Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 862-864

  Tashima, Karen T ^a,e   Caliendo, A M ^c   Ahmad, M ^b   Gormley, J M ^a   Fiske, W D ^d   Brennan, J M ^d   Flanigan, T P ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DUPONT COMPANY   (United States)

^e MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; OXAZINES; VIRAL LOAD; ZIDOVUDINE;

EID: 0032875534     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314945     Document Type: Article

References (15)

1. 1. Janssen RS. Epidemiology and neuroepidemiology of human immunodeficiency virus infection. In: Berger JR, Levy RM, eds. AIDS and the nervous system, 2d ed. Philadelphia: Lippincott-Raven, 1997: 21.
2. 2. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV Infection in 1998. JAMA 1998;280:78-86.
3. Th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999:208.
4. 4. Fiske WD, Nibbelink DW, Brennan JM, Mutlib AE, Ruiz NM. DMP 266 cerebrospinal fluid concentrations (CSF) after oral administration (abstract A12). In: Abstracts of the 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:55.
5. 5. Fiske WD, Brennan JM, Haines PJ, Mutlib AE, Gemzik B, and Gerson R. Efavirenz (DMP 266) cerebrospinal fluid (CSF) concentrations after chronic oral administration to cynomolgus monkeys [abstract 640]. In: Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Washington, DC: American Society for Microbiology, 1998:24.
6. 6. DuPont Pharmaceuticals Company, Development. Investigational Drug Brochure: DMP 266. April 1997.
7. 7. Portegies P. HIV-1, the brain, and combination therapy. Lancet 1995;346: 1244-5.
8. 8. Yazdanian M, Ratigan S, Joseph D, et al. Nevirapine, a non-nucleoside RT inhibitor, readily permeates the blood brain barrier [abstract 567]. In: Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1997:236.
9. 9. Collier AC, Marra C, Coombs RW, Zhong L, Stone J, Nguyen B-Y. Cerebrospinal fluid (CSF) indinavir (IDV) and HIV RNA levels in patients on chronic indinavir therapy [abstract 64]. In: Abstracts of the IDSA 35th Annual Meeting (San Francisco). Washington, DC: American Society for Microbiology, 1997:343.
10. 10. Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997;175:434-7.
11. 11. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol 1993;33:343-9.
12. 12. Foudraine NA, Hoetelmans RMW, Lange JMA, et al. Cerebrospinal fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998;351:1547-51.
13. 13. Gisslen M, Hagberg L, Svennerholm B, Norkrans G. HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy. AIDS 1997;11:1194.
14. 14. Farthing C, Japour A, Cohen C, et al. Cerebrospinal fluid (CSF) and plasma HIV RNA suppression with ritonavir (RIT)-saquinavir (SQV)in protease inhibitor naive patients [abstract 17]. In: Abstracts of the 37th Interscience conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:122.
15. 15. Skolnick AA. Protease inhibitors may reverse AIDS dementia. JAMA 1998;279:419.